UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025... Show more
UnitedHealth Group, the largest U.S. health insurer by revenue, has spent recent months rebuilding investor confidence after a difficult period marked by elevated medical costs and margin compression. Over the trailing 30 days, the stock advanced approximately 9%, reflecting a constructive response to a stronger-than-expected earnings report and a third consecutive lift to full-year guidance. The shares remain well below their all-time high, and the recovery so far has been driven primarily by operational execution and cost discipline rather than volume growth.
Broader managed-care sentiment improved in mid-October when UnitedHealth's results helped lift peers including Humana, CVS Health, and Centene, as investors weighed whether the sector's worst cost pressures have begun to ease.
UnitedHealth Group operates through two complementary businesses. UnitedHealthcare provides health benefits to individuals, employers, and government program beneficiaries, while Optum delivers care services, pharmacy solutions, and data-driven analytics. Optum's three units — Optum Health, Optum Insight, and Optum Rx — span value-based care delivery, health technology, and pharmacy benefit management.
The company's scale is a defining competitive advantage. UnitedHealthcare serves roughly 48 million people, and Optum touches more than 120 million patients and consumers. This breadth supports a diversified revenue base and allows the company to invest in technology and care-management capabilities that smaller competitors struggle to replicate. UnitedHealth is also a consistent capital returner, having raised its dividend for 17 consecutive years and repurchased billions of dollars in stock annually.
The most significant catalyst in the period was the third-quarter 2026 earnings report released in mid-October. The company reported adjusted earnings of $4.69 per share, comfortably above consensus estimates of roughly $4.14, and revenue of $112.7 billion, which edged past forecasts. The standout metric was the medical care ratio, which declined to 88.4% from 89.9% a year earlier, indicating that medical claims consumed a smaller share of premium revenue. The improvement reflected medical cost management, pricing discipline, benefit design changes, and about $610 million in favorable prior-period reserve development.
Management also raised its full-year 2026 adjusted earnings outlook to at least $20.50 per share, up from a prior range of $19.50 to $20.00. Within segments, UnitedHealthcare's operating margin expanded to 3.3% from 2.1% a year earlier, while Optum Health swung to stronger profitability even as its revenue declined 10% year over year following deliberate exits from lower-margin value-based care markets. Optum Insight grew revenue 3% on demand for AI-enabled documentation and payment-accuracy tools.
Despite the upbeat report, the immediate stock reaction was muted, with shares ending the reporting day roughly flat, as analysts suggested a beat-and-raise was already anticipated. The sustained advance in the following weeks reflected broader recognition that cost trends are bending in a more stable direction.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading bots. Tickeron offers hundreds of AI trading bots that collectively monitor thousands of tickers, but only the most relevant and highest-performing bots appear in this section. These bots vary in trading strategy, holding timeframe, and performance metrics, allowing users to compare approaches across different market conditions and asset types. The section is designed to help traders quickly identify strategies that are currently demonstrating strength. Investors interested in supplementing their own research with systematic, data-driven signals may find it useful to review the page regularly.
Several factors are likely to shape UnitedHealth's trajectory through the remainder of 2026 and into 2027. Medical cost trends remain the central variable: while the medical care ratio is improving, care intensity is still elevated relative to historical norms, and management has cautioned that it is not assuming a return to prior patterns. The No Surprises Act dispute process continues to add expense, with arbitration awards contributing meaningfully to commercial cost trends above 11%.
Investors will also monitor Medicaid margins, which management describes as being in a trough year, and the pace of recovery toward target levels. On the Medicare side, the company has deliberately reduced its senior membership by 935,000 since the end of 2025 as part of a portfolio retooling, and the 2027 annual enrollment period will test whether disciplined benefit design can stabilize membership and margins. Finally, the continued rollout of AI-enabled administrative tools across Optum and UnitedHealthcare — from chart summarization to claims processing — is expected to support efficiency gains, though the timing and magnitude of those benefits remain to be seen.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UNH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 30 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 65%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 53 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 100 of 240 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 42%.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare